title: Hyaluronic acid-chondroitin sulfate: a potential factor to select pure stress urinary incontinence in patients with interstitial cystitis⁄painful bladder syndrome and mixed incontinence symptoms.
abstract: OBJECTIVE
  Aim of the study was to validate the Hyaluronic acid-Chondroitin sulfate (HA-CS) as ex adiuvantibus criteria to identified patients with urgency symptoms related to interstitial cystitis/painful bladder syndrome (IC/PBS) and to obtained a population of patients with pure stress urinary incontinence.
  
  
  METHODS
  We retrospectively analysed clinical data of 17 patients with clinical suspect of IC/PBS, which received intravescical HA-CS to reduce pelvic pain and urgency symptoms waiting for surgical treatment for stress urinary incontinence. The main outcomes were reduction of urinary frequency, urgency, and bladder pain.
  
  
  RESULTS
  Compared to baseline, a significant decrease in pain, urgency and frequency were observed. Of the 17 patients, 82.3% reported resolution of pain and urge symptoms and in patients with persistence of urge symptoms the urodynamic assessment showed an overactive bladder syndrome (OAB).
  
  
  CONCLUSIONS
  HA-CS treatment induces an improvement in pain and urgency symptoms in patients with IC⁄PBS that referred also stress urinary incontinence. Therefore, HA-CS treatment could be use as clinical adjunctive parameter to select patients with pure stress urinary incontinence.
authors.affiliation: Department of Obstetrics and Gynecology, "Magna Graecia" University, Catanzaro, Italy - rita.mocciaro@hotmail.it.
authors.forename: M
authors.initials: M
authors.lastname: Morelli
authors.forename: R
authors.initials: R
authors.lastname: Mocciaro
authors.forename: R
authors.initials: R
authors.lastname: Venturella
authors.forename: A
authors.initials: A
authors.lastname: Albano
authors.forename: A
authors.initials: A
authors.lastname: Sacchinelli
authors.forename: F
authors.initials: F
authors.lastname: Zullo
mesh_terms: D000328:Adult; D002809:Chondroitin Sulfates / Q000008:administration & dosage* / Q000627:therapeutic use; D015331:Cohort Studies; D018856:Cystitis, Interstitial / Q000188:drug therapy* / Q000503:physiopathology; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D008875:Middle Aged; D017699:Pelvic Pain / Q000188:drug therapy / Q000209:etiology; D012189:Retrospective Studies; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy / Q000503:physiopathology; D014550:Urinary Incontinence, Stress; D053202:Urinary Incontinence, Urge / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates